Latest News:
Exclusive Interview: Dr. Stanley Schwartz
- SGLT-2s and Evidence-Based Medicine (transcript)
- Using Evidence-Based Practice (video)
Editor's Note
Whenever there is a black box warning on a medication, we have a natural hesitation to use in certain patients. Sometimes these warnings have real consequences, and sometimes they may be related to effects from another older drug in the same class. This was certainly the case with the biguanides, metformin and phenformin. Lactic acidosis was so common with phenformin that it was withdrawn from the market in 1957. Because of this fear, metformin, although available in Europe in 1956, was not approved in the U.S. till 1995.
Now we have a newer class of drugs that carry a warning that does not seem to be warranted. This month in our SGLT-2 inhibitor newsletter, we have some “evidence-based” information and statistics that may make you more likely to prescribe these medications in both type 1 and type 2 patients. Check out what Dr. Stanley Schwartz has to say about this new thinking on SGLT-2 use.
Dave Joffe
Editor-in-chie
Latest News
What are the benefits of dapagliflozin for type 1 when added to an insulin-liraglutide regimen?
Exclusive Interview: Dr. Stanley Schwartz
In this exclusive interview transcript, Dr. Stanley Schwartz discusses SGLT-2s and evidence-based medicine: the risk of DKA in Type 2 diabetes is just five in 10,000, compared to a benefit of 38% reduction in cardiovascular mortality.
In part 3 of this Exclusive Interview about the new diabetes classification, facilitating the individual use of “evidence-based practice” to individually assess the situation of a specific patient, instead of allowing media supposition about a drug class — such as SGLT-2s — to dictate diabetes treatment.